Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $5.29 and traded as high as $5.70. Aurinia Pharmaceuticals shares last traded at $5.57, with a volume of 682,487 shares trading hands.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on AUPH shares. StockNews.com raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research note on Friday, March 1st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Aurinia Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $10.00.
Check Out Our Latest Report on AUPH
Aurinia Pharmaceuticals Stock Performance
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last issued its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.14. The firm had revenue of $50.30 million during the quarter, compared to the consensus estimate of $46.30 million. Aurinia Pharmaceuticals had a negative net margin of 32.69% and a negative return on equity of 15.06%. On average, analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.15 EPS for the current year.
Institutional Trading of Aurinia Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vermillion & White Wealth Management Group LLC purchased a new position in Aurinia Pharmaceuticals during the 4th quarter worth $30,000. Tidemark LLC acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter worth approximately $39,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Aurinia Pharmaceuticals in the 3rd quarter valued at approximately $65,000. Virtu Financial LLC acquired a new position in shares of Aurinia Pharmaceuticals in the first quarter valued at approximately $78,000. Finally, Eagle Asset Management Inc. acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $92,000. 36.83% of the stock is owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
- Five stocks we like better than Aurinia Pharmaceuticals
- How to Choose Top Rated Stocks
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Progress Software Stock Back in the Green After Beating Forecasts
- How to Calculate Return on Investment (ROI)
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.